This strategy recovered known targets of small-molecule inhibitors, including PDGFRB, CDK6, and PARP1, that have been (13, 34) or are being (ClinicalTrials.gov: NCT03110744 and NCT03127215) tested in clinical trials enrolling patients with chordoma, demonstrating the potential to identify druggable molecules among the TBXT-regulated proteins. This evidence concerns the gene PARP1 and chordoma.